MDM2 and meningioma: Furthermore, several biomarkers including polycystin-2, S100, p14, p15, p27, p73, pAKT, cadherin E, caspase 3a, β-catenin, cathepsin, CD44, MDM2, MMP9, PDGF, PTEN, survivin, and β-TGF did not associate with RFS (p>0.05) [26, 31, 64, 69, 99] and considered not suitable as the prognostic biomarkers for meningioma patients.